The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.
About Company
Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.
The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).
QBLās key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipmentās & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.
It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipmentās and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipmentās and devices as per the technical collaboration and specifications provided by the partners or companies.
With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.
Issue Details / Capital History
The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.
The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.
The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM groupās Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.
The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 ā Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.
Post-IPO, companyās current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.
IPO Lead Managers & Registrar
Financial Performance
On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.
For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.
If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.
For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.
All amounts in Indian Rupees crores
Period Ended
Revenue
Expense
PAT
Assets
2023
ā¹184.81
ā¹154.97
ā¹32.10
ā¹251.58
2024
ā¹206.45
ā¹175.85
ā¹34.44
ā¹339.25
2025
ā¹322.58
ā¹261.43
ā¹28.13
ā¹455.49
Dec 2025
ā¹236.50
ā¹186.96
ā¹38.69
ā¹561.34
Dividend Policy
The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.
Comparison with Listed Peers - for Fiscal 2025
As per the offer document, the company has no listed peers to compare with.
Name of the Company
Face Value (ā¹)
EPS basic (ā¹)Ā
EPS Diluted (ā¹)
RONW (%)
P/E Ratio
NAV (ā¹)
Powerica Limited
5
15.26Ā
15.26
15.37 %Ā
24.45
99.76
Listed Peers
Cummins India Limited
2
72.15Ā
72.15
26.45%
64.13Ā
272.78
Kirloskar Oil Engines Limited
2
33.71
33.60
15.85%
43.24
212.60
NTPC Green Energy Limited
10
0.67
0.67
2.58%
129.40
21.88
Acme Solar Holdings Limited
2
4.55
4.53
5.59%
50.74Ā
74.54
Adani Green Energy Limited
10
8.37
8.37
11.90%Ā
101.53Ā
76.62
Disclaimer: Above table shows earnings and P/E ratio as of 2025-26
Merchant Banker's Track Record
The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.
Conclusion - Apply for medium to long term
QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.
Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.
He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.
Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.
FAQ Accordion
Q-Line Biotech IPO FAQs
1. What is Q-Line Biotech IPO?
ā
Q-Line Biotech IPO is SME IPO. The company is going to raise ā¹214 Crores via IPO. The issue is priced at ā¹326 to ā¹343 per equity share. The IPO is to be listed on NSE SME.
2. When Q-Line Biotech IPO will open for subscription?
ā
The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.
3. What is Q-Line Biotech IPO Investors Portion?
ā
The investorsā portion for QIB is 50%, NII is 15%, and Retail is 35%.
4. How to Apply the Q-Line Biotech IPO?
ā
You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.
5. What is Q-Line Biotech IPO Issue Size?
ā
Q-Line Biotech IPO issue size is ā¹214 crores.
6. What is Q-Line Biotech IPO Price Band?
ā
Q-Line Biotech IPO Price Band is ā¹326 to ā¹343.
7. What is Q-Line Biotech IPO Lot Size?
ā
The minimum bid is 800 Shares with ā¹2,74,400 amount.
8. What is the Q-Line Biotech IPO Allotment Date?
ā
Q-Line Biotech IPO allotment date is May 26,2026.
9. What is the Q-Line Biotech IPO Listing Date?
ā
Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.
Caliber Mining IPO open date is July 17, 2026 and the IPO will close on July 21, 2026. Caliber Mining IPO is a Book build Issue. The company to raise around ā¹600 crores via IPO that comprises fresh issue of ā¹500 crores and offer for sale up to [.] equity shares with face value of ā¹10 each.
Caliber Mining IPO price band is ā¹[.] to ā¹[.] per share. The retail quota is 35%, QIB is 50%, and HNI is 15%. Caliber Mining IPO to list on BSE, NSE on July 24, 2026. The allotment of Caliber Mining IPO date is July 22, 2026.
The company reported revenue of ā¹958.18 crores in 2026 against ā¹662.34 crores in 2025. The company reported profit of ā¹95.12 crores in 2026 against profit of ā¹93.19 crores in 2025. As per the financials, the IPO investors should apply the IPO for a long term.
The Caliber Mining IPO minimum market lot is [.] shares with ā¹[.] application amount. The retail investors can apply up-to 13 lots with [.] shares of ā¹[.] amount.
Application
Lot Size
Shares
Amount
Retail Minimum
–
–
ā¹-
Retail Maximum
–
–
ā¹-
S-HNI Minimum
–
–
ā¹-
S-HNI Maximum
–
–
ā¹-
B-HNI Minimum
–
–
ā¹-
IPO Reservation
Investor Category
Share Offered
-% Shares
Anchor Investor
– Shares
-%
QIB (Ex. Anchor)
– Shares
50%
NII Shares Offered
– Shares
15%
Retail Shares Offered
– Shares
35%
Caliber Mining IPO Anchor Investors
Anchor Bidding Date
2026
Anchor Investors List
Shares Offered
[.] Shares
Anchor Size
[.] Cr.
lock-in period end date 50% shares (30 Days)
2026
lock-in period end date 50% shares (90 Days)
2026
Caliber Mining IPO Dates
The Caliber Mining IPO date is July 17 and the close date is July 21. The Caliber Mining IPO allotment will be finalized on July 22 and the IPO listing on July 24.
IPO Open Date:
July 17, 2026
IPO Close Date:
July 21, 2026
Basis of Allotment:
July 22, 2026
Refunds:
July 23, 2026
Credit to Demat Account:
July 23, 2026
IPO Listing Date:
July 24, 2026
Promoters and Holding Pattern
The promoters of the company are Mohit Satishkumar Chadda, Anuj Krishanlal Chadda, Manish Krishanlal Chadda, Rahul Roshanlal Chadda and Priya Anuj Chadda.
Particular
Shares
% Share
Promoter Holding Pre Issue
5,35,83,333
94.91%
Promoter Holding Post Issue
–
-%
Objects of the Issue & Utilisation of proceeds
Purpose
Crores
Repayment/ prepayment, in full or part, of certain borrowings availed by the Company
ā¹175.00
Funding capital expenditure for purchase of machinery
ā¹200.00
General Corporate Purpose
ā¹-
About Caliber Mining IPO
To be updated soon
Caliber Mining IPO Company Financial Report
Amount ā¹ in Crores
Period Ended
Revenue
Expense
PAT
Assets
2022
ā¹379.57
ā¹315.86
ā¹44.31
ā¹417.60
2023
ā¹662.34
ā¹535.51
ā¹93.19
ā¹729.81
2024
ā¹958.18
ā¹830.49
ā¹95.12
ā¹1,259.93
Caliber Mining IPO Valuation – FY2024
Check Caliber Mining IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
Caliber Mining IPO is Mainboard IPO. The company is going to raise ā¹600 Crores via IPO. The issue is priced at ā¹[.] to ā¹[.] per equity share. The IPO is to be listed on BSE & NSE.
When Caliber Mining IPO will open for subscription?
The IPO is to open on July 17, 2026 for QIB, NII, and Retail Investors. The IPO will close on July 21, 2026.
What is Caliber Mining IPO Investors Portion?
The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.
How to Apply the Caliber Mining IPO?
You can apply for Caliber Mining IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.
What is Caliber Mining IPO Issue Size?
Caliber Mining IPO issue size is ā¹600 crores.
What is Caliber Mining IPO Price Band?
Caliber Mining IPO Price Band is ā¹[.] to ā¹[.].
What is Caliber Mining IPO Lot Size?
The minimum bid is [.] Shares with ā¹[.] amount.
What is the Caliber Mining IPO Allotment Date?
Caliber Mining IPO allotment date is July 22, 2026.
What is the Caliber Mining IPO Listing Date?
Caliber Mining IPO listing date is July 24, 2026. The IPO is to list on BSE & NSE.
Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.
